Impact of baseline methamphetamine/amphetamine use on discontinuation of methadone and buprenorphine/naloxone among people with prescription‐type opioid use disorder in Canada

Documenti analoghi

• Characterising methamphetamine/amphetamine use among opioid agonist therapy‐seeking adults with prescription‐type opioid use disorder in Canada
  di: Jenna Langlois, et al.
  Pubblicazione: (2024)
• Cannabis use patterns and comparison trends in Canada
  di: Benedikt Fischer, et al.
  Pubblicazione: (2025)
• Response to Hall et al.: Prescription psychostimulants for amphetamine‐type stimulant use disorder ‐ acknowledging challenges but not giving up on its potential cost‐effectiveness
  di: Heidar Sharafi, et al.
  Pubblicazione: (2024)
• Sexually transmitted and blood‐borne infection risk reduction with methadone and buprenorphine/naloxone among people with prescription‐type opioid use disorder: Findings from a Canadian pragmatic randomized trial
  di: M. Eugenia Socias, et al.
  Pubblicazione: (2024)
• Commentary on Coelho et al .: Ecological momentary assessments may be key to the future of cannabis studies
  di: Lucy Chester, et al.
  Pubblicazione: (2025)